Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for myocardial infarction
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on myocardial infarction or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on myocardial infarction and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Comparison of procainamide and mexiletine in prevention of ventricular arrhythmias after acute myocardialinfarction. The incidence of ventricular arrhythmias after myocardialinfarction has been compared in a controlled study of procainamide, mexiletine, and placebo. Sixty male patients who has sustained a myocardialinfarction and had received lignocaine for ventricular tachycardia or ventricular ectopic beats which were R-on-T, multiform, or close-coupled took part. The efficacy of the drugs (...) compared with 95% of those receiving mexiletine, both drugs were equally effective antiarrhythmically. The only major adverse effect of therapy noted was development of a positive antinuclear factor in a procainamide-treated patient. These results demonstrate the efficacy of oral antiarrhythmic agents in the management of ventricular arrhythmias after acute myocardialinfarction. Mexiletine has the advantage of less frequent administration and lower toxicity.
A double-blind trial of patient-controlled nitrous-oxide/oxygen analgesia in myocardialinfarction. The analgesic effect of self-administered nitrous oxide 50%/oxygen 50% ('Entonox" analgesic apparatus) was compared with air given by the same method in a double-blind trial in 81 patients with myocardialinfarction. Self-administered nitrous oxide/oxygen, which was associated with a low frequency of side-effects, proved significantly more effective than air in the early relief of severe cardiac
Value of early ambulation in patients with and without complications after acute myocardialinfarction. A prospective, controlled, randomized study was done to compare the effect of early and late ambulation in hospitalized patients with acute myocardialinfarction. All patients surviving longer than the first five days were studied; 64 patients were mobilized on day six and discharged on day 12, and 65 were mobilized on day 13 and discharged on day 19. Follow-up observation lasted from six
Controlled trial of urokinase in myocardialinfarction. A European Collaborative Study. 341 patients with acute myocardialinfarction have been treated in intensive or coronary care units. They were randomised into two groups, 172 receiving urokinase and 169 receiving a glucose infusion. Thereafter they were anticoagulated first with heparin and then for a year with oral anticoagulants. Despite a significantly faster regression of electrocardiographic alterations in the urokinase group
Anticoagulant therapy after acute myocardialinfarction. Relation of therapeutic benefit to patient's age, sex, and severity of infarction. 4117261 1973 01 05 2016 10 17 0098-7484 222 5 1972 Oct 30 JAMA JAMA Anticoagulant therapy after acute myocardialinfarction. Relation of therapeutic benefit to patient's age, sex, and severity of infarction. 541-8 Drapkin A A Merskey C C eng Clinical Trial Journal Article Randomized Controlled Trial United States JAMA 7501160 0098-7484 0 Anticoagulants 0 (...) Placebos 5M7Y6274ZE Phenindione 5Q7ZVV76EI Warfarin 7QID3E7BG7 Dicumarol 9005-49-6 Heparin AIM IM Age Factors Aged Anticoagulants adverse effects therapeutic use Cerebrovascular Disorders mortality Clinical Trials as Topic Diabetes Complications Dicumarol therapeutic use Electrocardiography Female Heart Failure complications Hemorrhage chemically induced Heparin therapeutic use Humans Hypertension complications Male Middle Aged MyocardialInfarction complications drug therapy mortality Phenindione